This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Cipollone, F Search for Related Content PubMed PubMed Citation Articles by Cipollone, F Social Bookmarking                         What's this?

COX-2 and prostaglandins in atherosclerosis

Atherosclerosis Prevention Center, "G. d’Annunzio" University of Chieti, and Clinical Research Center, "G. d’Annunzio" University Foundation, Chieti, Italy, fcipollone{at}unich.it

Arachidonic acid metabolism is involved in acute ischemic syndromes affecting the coronary or cerebrovascular territory, as demonstrated by biochemical measurements of eicosanoid biosynthesis and the results of inhibitor trials in these settings. In particular, the efficacy of low-dose aspirin in reducing the complications of acute ischemic syndromes has focused attention on the cyclooxygenase (COX) pathway of arachidonic acid metabolism and its products, collectively termed prostanoids.

Two cyclooxygenase (COX)-isozymes have been characterized, COX-1 and COX-2, that differ in terms of regulatory mechanisms of expression, tissue distribution, substrate specificity and preferential coupling to upstream and downstream enzymes. While the role of platelet COX-1 in acute ischemic diseases is firmly established, the role of COX-2 in atherothrombosis is still uncertain. Studies from our group suggest that variable expression of upstream and downstream enzymes in the prostanoid biosynthesis may represent important determinants of the functional consequences of COX-2 expression and inhibition in different clinical settings.

Key Words: atherosclerosis • COX-2 • inflammation • prostaglandins

Lupus, Vol. 14, No. 9, 756-759 (2005)
DOI: 10.1191/0961203305lu2215oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Y. M. Kim, S.-Y. Park, and H. Pyo Cyclooxygenase-2 (COX-2) Negatively Regulates Expression of Epidermal Growth Factor Receptor and Causes Resistance to Gefitinib in COX-2-Overexpressing Cancer Cells Mol. Cancer Res., August 1, 2009; 7(8): 1367 - 1377. [Abstract] [Full Text] [PDF]